Larimar Therapeutics, Inc.
LRMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.16 | -0.53 | -0.02 |
| FCF Yield | -11.37% | -10.48% | -19.33% | -8.91% |
| EV / EBITDA | -3.51 | -6.10 | -3.90 | -7.01 |
| Quality | ||||
| ROIC | -34.52% | -22.33% | -20.91% | -17.69% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.60 | 0.74 | 0.91 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -48.33% | 27.04% | -20.89% | 10.62% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | 0.58 | 0.52 | 0.90 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |